Why Is Insulet (PODD) Down 8.7% Since Last Earnings Report?

05.06.26 17:30 Uhr

Werte in diesem Artikel
Aktien

139,30 EUR 4,10 EUR 3,03%

It has been about a month since the last earnings report for Insulet (PODD). Shares have lost about 8.7% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Insulet due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.Insulet Tops Q4 Earnings & Revenue EstimatesInsulet Corporation reported first-quarter 2026 adjusted earnings per share of $1.42, up 39.7% from the year-ago period’s figure. The bottom line surpassed the Zacks Consensus Estimate by 24.8%.GAAP earnings per share were $1.30 compared with 50 cents from the year-ago quarter. PODD’s RevenuesRevenues totaled $761.7 million, which beat the Zacks Consensus Estimate by 4.6%. The top line jumped 33.9% year over year and 30.1% at constant exchange rate or CER, which exceeded the company’s high end of the guidance range of 25-27%.PODD’s 2026 OutlookInsulet updated its revenue guidance for full-year 2026. Total revenues are now projected to grow 21-23% at CER. The Zacks Consensus Estimate for the company’s 2026 revenues is currently pinned at $3.32 billion, implying 22.4% year-over-year growth. Adjusted EPS is expected to grow more than 25% year over year in 2026. The Zacks Consensus Estimate for the company’s 2026 EPS is currently pegged at $6.43, implying 29.4% year-over-year growth.For the second quarter, Insulet projects revenue growth of 20-22%. The consensus estimate for the company’s second-quarter revenues is currently pegged at $787.5 million, implying 21.3% year-over-year growth. How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a upward trend in estimates review.VGM ScoresAt this time, Insulet has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock has a score of C on the value side, putting it in the middle 20% for value investors.Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Insulet has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.Performance of an Industry PlayerInsulet is part of the Zacks Medical - Products industry. Over the past month, Stryker (SYK), a stock from the same industry, has gained 2.4%. The company reported its results for the quarter ended March 2026 more than a month ago.Stryker reported revenues of $6.02 billion in the last reported quarter, representing a year-over-year change of +2.6%. EPS of $2.60 for the same period compares with $2.84 a year ago.Stryker is expected to post earnings of $3.49 per share for the current quarter, representing a year-over-year change of +11.5%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.5%.Stryker has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>This article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Insulet und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Quelle: Zacks

Nachrichten zu Insulet Corp Shs

Analysen zu Insulet Corp Shs

DatumRatingAnalyst
06.05.2019Insulet BuyBTIG Research
09.03.2018Insulet OutperformBMO Capital Markets
22.02.2018Insulet OverweightBarclays Capital
03.11.2017Insulet BuyCanaccord Adams
15.09.2017Insulet OverweightBarclays Capital
DatumRatingAnalyst
06.05.2019Insulet BuyBTIG Research
09.03.2018Insulet OutperformBMO Capital Markets
22.02.2018Insulet OverweightBarclays Capital
03.11.2017Insulet BuyCanaccord Adams
15.09.2017Insulet OverweightBarclays Capital
DatumRatingAnalyst
17.07.2017Insulet NeutralBTIG Research
08.07.2015Insulet NeutralRobert W. Baird & Co. Incorporated
01.05.2015Insulet PerformOppenheimer & Co. Inc.
27.02.2015Insulet PerformOppenheimer & Co. Inc.
18.02.2015Insulet HoldCanaccord Adams
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Insulet Corp Shs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen